451 related articles for article (PubMed ID: 29428473)
1. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212).
Ito M; Kobayashi A; Fujita S; Mizusawa J; Kanemitsu Y; Kinugasa Y; Komori K; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Akasu T; Moriya Y;
Eur J Surg Oncol; 2018 Apr; 44(4):463-468. PubMed ID: 29428473
[TBL] [Abstract][Full Text] [Related]
2. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
3. Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212.
Saito S; Fujita S; Mizusawa J; Kanemitsu Y; Saito N; Kinugasa Y; Akazai Y; Ota M; Ohue M; Komori K; Shiozawa M; Yamaguchi T; Akasu T; Moriya Y;
Eur J Surg Oncol; 2016 Dec; 42(12):1851-1858. PubMed ID: 27519616
[TBL] [Abstract][Full Text] [Related]
4. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.
Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Kinugasa Y; Komori K; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Murata K; Akagi Y; Takiguchi N; Saida Y; Nakamura K; Fukuda H; Akasu T; Moriya Y;
Ann Surg; 2017 Aug; 266(2):201-207. PubMed ID: 28288057
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of pathological lateral pelvic lymph node metastasis in patients without clinical lateral pelvic lymph node metastasis (clinical stage II/III): The analysis of data from the clinical trial (JCOG0212).
Komori K; Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Shiomi A; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Kinugasa Y; Takii Y; Akasu T; Moriya Y;
Eur J Surg Oncol; 2019 Mar; 45(3):336-340. PubMed ID: 30477950
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic Versus Open Lateral Lymph Node Dissection for Locally Advanced Low Rectal Cancer: A Subgroup Analysis of a Large Multicenter Cohort Study in Japan.
Yamaguchi T; Konishi T; Kinugasa Y; Yamamoto S; Akiyoshi T; Okamura R; Ito M; Nishimura Y; Shiozawa M; Yamaguchi S; Hida K; Sakai Y; Watanabe M
Dis Colon Rectum; 2017 Sep; 60(9):954-964. PubMed ID: 28796734
[TBL] [Abstract][Full Text] [Related]
7. Male urinary and sexual functions after mesorectal excision alone or in combination with extended lateral pelvic lymph node dissection for rectal cancer.
Akasu T; Sugihara K; Moriya Y
Ann Surg Oncol; 2009 Oct; 16(10):2779-86. PubMed ID: 19626377
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212).
Tsukamoto S; Fujita S; Ota M; Mizusawa J; Shida D; Kanemitsu Y; Ito M; Shiomi A; Komori K; Ohue M; Akazai Y; Shiozawa M; Yamaguchi T; Bando H; Tsuchida A; Okamura S; Akagi Y; Takiguchi N; Saida Y; Akasu T; Moriya Y;
Br J Surg; 2020 Apr; 107(5):586-594. PubMed ID: 32162301
[TBL] [Abstract][Full Text] [Related]
9. A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study).
Ohue M; Iwasa S; Kanemitsu Y; Hamaguchi T; Shiozawa M; Ito M; Yasui M; Katayama H; Mizusawa J; Shimada Y;
Jpn J Clin Oncol; 2017 Jan; 47(1):84-87. PubMed ID: 27655905
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND.
Kanemitsu Y; Komori K; Shida D; Ochiai H; Tsukamoto S; Kinoshita T; Moriya Y
Surgery; 2017 Aug; 162(2):303-314. PubMed ID: 28366499
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of survival and functional outcomes after total mesorectal excision with or without lateral pelvic lymph node dissection in rectal cancer surgery.
Hajibandeh S; Hajibandeh S; Matthews J; Palmer L; Maw A
Surgery; 2020 Sep; 168(3):486-496. PubMed ID: 32620303
[TBL] [Abstract][Full Text] [Related]
12. Mesorectal excision with or without lateral lymph node dissection for elderly patients with mid-low rectal cancer: safety and feasibility analysis.
Zhou S; Mei S; Feng B; Yang Y; Wang X; Wang Q; Liu Q;
Jpn J Clin Oncol; 2023 Jan; 53(1):26-34. PubMed ID: 36354102
[TBL] [Abstract][Full Text] [Related]
13. [Comparison on efficacy between fascia-oriented versus vascular-oriented lateral lymph node dissection in patients with rectal cancer].
Wang ZJ; Liu Z; Liang JW; Zhang MG; Mei SW; Shen HY; Chen JN; Li J; Zhao FQ; Wei FZ; Xiao TX; Liu Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jul; 24(7):611-618. PubMed ID: 34289546
[No Abstract] [Full Text] [Related]
14. Impact of autonomic nerve preservation and lateral node dissection on male urogenital function after total mesorectal excision for lower rectal cancer.
Kyo K; Sameshima S; Takahashi M; Furugori T; Sawada T
World J Surg; 2006 Jun; 30(6):1014-9. PubMed ID: 16736330
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of lateral node metastasis from lower rectal cancer].
Moriya Y; Akasu T; Fujita S; Yamamoto S; Inada R; Takawa M
Nihon Geka Gakkai Zasshi; 2011 Sep; 112(5):325-9. PubMed ID: 21941823
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic mesorectal excision with preservation of the pelvic autonomic nerves for rectal cancer.
Fukunaga Y; Higashino M; Tanimura S; Kishida S; Fujiwara Y; Ogata A; Osugi H
Hepatogastroenterology; 2007; 54(73):85-90. PubMed ID: 17419237
[TBL] [Abstract][Full Text] [Related]
18. Outcome of lateral pelvic lymph node dissection with total mesorectal excision in treatment of rectal cancer: A systematic review and meta-analysis.
Emile SH; Elfeki H; Shalaby M; Sakr A; Kim NK
Surgery; 2021 May; 169(5):1005-1015. PubMed ID: 33317903
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcomes of robotic-assisted laparoscopic versus open lateral lymph node dissection for locally advanced low rectal cancer.
Yamaguchi T; Kinugasa Y; Shiomi A; Kagawa H; Yamakawa Y; Furutani A; Manabe S; Yamaoka Y; Hino H
Surg Endosc; 2018 Nov; 32(11):4498-4505. PubMed ID: 29721748
[TBL] [Abstract][Full Text] [Related]
20. Application of indocyanine green-enhanced near-infrared fluorescence-guided imaging in laparoscopic lateral pelvic lymph node dissection for middle-low rectal cancer.
Zhou SC; Tian YT; Wang XW; Zhao CD; Ma S; Jiang J; Li EN; Zhou HT; Liu Q; Liang JW; Zhou ZX; Wang XS
World J Gastroenterol; 2019 Aug; 25(31):4502-4511. PubMed ID: 31496628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
